The Filing Desk

Fulgent Genetics

FLGT · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

FLGT · Last close · November 19, 2026
$24.78
Value Fulgent Genetics yourself

Fulgent Genetics' revenue rose 13.8% to $323 million in fiscal 2025. Its operating margin was −28.2%, down from −26.1% a year earlier. Free cash flow was −$124 million. It paid out $11 million in dividends and buybacks. The diluted share count rose 1.8%.

FULGENT GENETICS, INC. Latest fiscal year ended December 31, 2025 10-K filed February 27, 2026 · 0001193125-26-079169 Updated
Revenue
$323M
13.8%
Operating margin
−28.2%
2.2 pts
Net income
−$60M
 
Free cash flow
−$124M
 
Return on capital
−8.7%
2.6 pts
Market cap
$686M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Fulgent Genetics does

Fulgent Genetics has two businesses: laboratory services and therapeutic development. It was founded in 2011 to offer flexible and affordable genetic and diagnostic tests.

Its laboratory services business provides testing and interpretation by licensed physicians. These include anatomic pathology, such as gastrointestinal and skin pathology, and precision diagnostics, such as genetic sequencing tests for rare diseases, hereditary cancer and reproductive health. It also offers testing and licensing to drug and biotech companies and research organizations, which it calls BioPharma services, and a telemedicine platform called Picture that lets consumers start their own testing.

Its therapeutic development business, Fulgent Pharma, was acquired in 2022. It works on cancer drug candidates that use a nanoencapsulation platform, which wraps drugs in tiny capsules to control how they are released. The company says its long-term aim is to move from diagnostics to a fully integrated precision medicine company. It says its revenue is often concentrated in a single large customer or a few larger ones.

Its biggest risks, as it describes them

  • It has a history of losses and may not regain or sustain profitability.
  • Its revenue is often concentrated among one large customer or a few, so losing one could hurt it.
  • Its results can swing a lot from period to period and are hard to predict.
  • It may not collect payment for the tests it delivers, and may fail to integrate businesses it buys.
From Fulgent Genetics's annual report on Form 10-K, filed February 27, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2020 to 2022, earnings per share fell 27.9% a year and net income 18.2% a year, as new shares raised the share count by 29% and diluted each share's earnings. Fulgent Genetics then lost money in fiscal 2023, 2024 and 2025.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments—8098258336
Debt incl. finance leases—12643
Net debt (negative means net cash)—−68−92−254−333
Net debt to EBITDA—−0.3x———
Debt to equity—0.0x0.0x0.0x0.0x
Interest coverage5,777.4x516.0x−400.7x−434.8x−1,214.6x
Current ratio5.8x7.1x7.0x4.8x6.5x
Quick ratio5.8x7.1x7.0x4.8x6.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Fulgent Genetics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Fulgent Genetics shares on the open market, and 2 insiders sold $386,628.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 2, 2026Jian XiePresident and COOSold2,127$19.66$41,817Form 4
Sep 2, 2026Hanlin GaoChief Scientific OfficerSold1,673$19.66$32,891Form 4
Aug 27, 2026Jian XiePresident and COOSold1,193$19.91$23,753Form 4
Aug 27, 2026Hanlin GaoChief Scientific OfficerSold939$19.91$18,695Form 4
Jun 2, 2026Jian XiePresident and COOSold2,146$17.89$38,392Form 4
Jun 2, 2026Hanlin GaoChief Scientific OfficerSold1,688$17.89$30,198Form 4
May 27, 2026Jian XiePresident and COOSold1,201$17.60$21,138Form 4
May 27, 2026Hanlin GaoChief Scientific OfficerSold945$17.60$16,632Form 4
Dec 2, 2025Jian XiePresident and COOSold1,140$28.33$32,296Form 4
Dec 2, 2025Hanlin GaoChief Scientific OfficerSold1,075$28.33$30,455Form 4
Nov 28, 2025Jian XiePresident and COOSold1,198$29.57$35,425Form 4
Nov 28, 2025Hanlin GaoChief Scientific OfficerSold943$29.57$27,885Form 4
The latest 12 of 14 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 96 of 94 of 9
Rule of 40−51.6%−8.8%−24.7%
Altman Z''14.5815.7414.32
Accruals ratio−14.9%−5.2%3.4%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positivePassPassFail
Return on assets roseFailPassFail
Cash from operations exceeds net incomePassPassFail
Debt fell relative to assetsPassPassPass
Current ratio roseFailFailPass
Share count didn't risePassFailFail
Gross margin roseFailPassPass
Revenue rose relative to assetsFailPassPass
F-score4 of 96 of 94 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Fulgent Genetics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Fulgent GeneticsFY2513.8%−28.2%−38.5%−8.7%—4
DocGoFY25−47.7%−55.3%9.3%−84.6%—3Compare
Castle BiosciencesFY253.7%−12.4%8.2%−19.1%—4Compare
CareDxFY2513.8%−8.1%—−20.0%—4Compare
Viemed HealthcareFY2520.5%8.5%4.4%12.4%−0.0x5Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue18192132422993619289284323
Revenue growth90.8%2.5%14.0%52.4%1,196.5%135.4%−37.6%−53.3%−2.0%13.8%
Gross profit12101118332777367104107131
Research and development4466122429414954
Operating income1−4−5−0290676178−196−74−91
Net income−5−2−6−0214507143−168−43−60
Diluted EPS (US$)—−0.14−0.31−0.028.9116.384.63−5.63−1.41−1.97
Diluted shares (millions)14181819243131303031
Cash flow
Cash from operations41−161415392542721−102
Capital expenditure4321352419224023
Free cash flow1−2−341065152355−19−124
Dividends paid0000000000
Share buybacks12000007425011
Acquisitions0000062173004
Stock-based compensation522381633434440
Balance sheet at fiscal year end
Cash and short-term investments8263128299—8098258336
Debt incl. finance leases——————12643
Total assets585754897001,2791,3861,2351,2201,214
Total liabilities433613111311610291107
Shareholders' equity545451835691,1591,2671,1361,1331,112
Margins and ratios
Gross margin63.2%54.4%49.9%56.6%78.7%78.3%59.3%36.1%37.8%40.6%
Operating margin5.0%−18.6%−23.8%−1.3%68.8%68.1%28.8%−67.6%−26.1%−28.2%
Net margin−29.3%−13.4%−26.3%−1.3%50.8%51.1%23.2%−58.0%−15.1%−18.8%
Free cash flow margin3.4%−8.3%−14.0%13.3%25.0%51.9%37.9%1.7%−6.8%−38.5%
Rule of 40 (growth + FCF margin)94.2%−5.9%−0.0%65.7%1,221.5%187.2%0.3%−51.6%−8.8%−24.7%
Return on capital———————−13.8%−6.1%−8.7%
Return on equity−17.9%−4.6%−10.7%−0.6%65.7%58.7%11.8%−14.0%−3.8%−5.4%
Return on assets−16.7%−4.4%−10.1%−0.6%54.3%51.3%10.8%−12.8%−3.5%−5.0%
Net debt to EBITDA——————−0.3x———
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Fulgent Genetics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Fulgent Genetics.